The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease
Answers
Answered by
0
Denosumab treatment was more efficacious than treatment with zoledronic acid in delaying or preventing HCM in advanced cancer patients with breast cancer, other solid tumours or multiple myeloma.
Answered by
0
bstract Background: We compared the activity of denosumab with zoledronic acid for
delaying or preventing hypercalcaemia of malignancy (HCM) in patients with advanced can-
cer and bone metastases or with multiple myeloma.
Methods: Patient-level data were combined from two identically designed, randomised,
double-blind, active-controlled, phase III trials of advanced cancer patients with breast cancer
and other solid tumours (excluding breast or prostate cancer) or multiple myeloma.
End-points included time to first on-study HCM, time to first and subsequent on-study
HCM, proportion of patients experiencing HCM and proportion of patients experiencing
recurrent HCM.
delaying or preventing hypercalcaemia of malignancy (HCM) in patients with advanced can-
cer and bone metastases or with multiple myeloma.
Methods: Patient-level data were combined from two identically designed, randomised,
double-blind, active-controlled, phase III trials of advanced cancer patients with breast cancer
and other solid tumours (excluding breast or prostate cancer) or multiple myeloma.
End-points included time to first on-study HCM, time to first and subsequent on-study
HCM, proportion of patients experiencing HCM and proportion of patients experiencing
recurrent HCM.
Similar questions